Omega-3 Prescription Drugs Market Outlook:
Omega-3 Prescription Drugs Market size was valued at USD 1.51 billion in 2025 and is set to exceed USD 2.92 billion by 2035, registering over 6.8% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of omega-3 prescription drugs is estimated at USD 1.6 billion.
The omega-3 prescription drugs market has grown significantly based on increasing awareness about health benefits attributed to these fatty acids, associated particularly with the prevention of cardiovascular diseases. Fundamentally, active ingredients such as EPA and DHA reduce triglyceride levels effectively and are highly in demand for reducing heart diseases. Thus, prescription drugs such as Vascepa and Lovaza are becoming popular in the healthcare industry. Better drug formulations and access to improved healthcare services have created significant opportunities for manufacturers in this sector.
Several governments worldwide now recognize the significant contribution that omega-3 can make to improving public health and are actively advocating research and healthcare reforms to extend their reach and visibility. As omega-3 supplements are presumed to provide health benefits, especially in the prevention of heart diseases and stroke, their use has gained popularity, with the Centers for Disease Control and Prevention (CDC) estimating that American adults, 5.4% of age group 20 to 39, 12.5% of age group 40 to 59, currently use omega-3 supplements. This represents a growing trend in preventive healthcare and heightened interest in proactive health management by consumers.
